The bill mandates coverage for the use of intravenous immunoglobulin (IVIG) to treat pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). Effective January 1, 2024, it repeals Arkansas Code 23-79-1903, which established the Arkansas PANS/PANDAS Advisory Council, and also repeals the sunset provision in Arkansas Code 23-79-1904. The bill amends Arkansas Code 23-79-1905 to require health benefit plans to provide coverage for IVIG treatment, contingent upon a patient-specific treatment plan developed by a primary care physician in consultation with specialists.

Additionally, the bill includes provisions for the Insurance Commissioner to develop rules for implementing this coverage, with a deadline for promulgation set for August 31, 2023. It establishes an emergency clause, indicating the immediate necessity of the act to ensure that affected children receive appropriate treatment options. The bill emphasizes the importance of timely access to care for children diagnosed with these conditions, aiming to improve their health outcomes and quality of life.

Statutes affected:
Old version SB181 Original - 1-27-2023 02:27 PM: 23-79-1903, 23-79-1904, 23-79-1905